Literature DB >> 15339862

Bolus injection of human UII in conscious rats evokes a biphasic haemodynamic response.

Sheila M Gardiner1, Julie E March, Philip A Kemp, Terence Bennett.   

Abstract

A biphasic cardiovascular response to bolus i.v. injection of human urotensin II (hUII, 3 nmol kg(-1)) in conscious, male, Sprague-Dawley (SD) rats was identified and underlying mechanisms were explored. Initially (0-5 min) there was tachycardia, hypotension and mesenteric and hindquarters vasodilatation; later (30-120 min), tachycardia, hindquarters vasodilatation and a modest rise in blood pressure occurred. Pretreatment with indomethacin or N(G) nitro-l-arginine methylester (l-NAME) reduced the mesenteric vasodilator response to hUII, and abolished the late tachycardia and hindquarters vasodilatation. Indomethacin also abolished the hypotension and early hindquarters vasodilatation, and substantially reduced the initial tachycardia. Indomethacin and l-NAME together prevented all haemodynamic responses to hUII. Inhibition of inducible NOS had no effect on responses to hUII, whereas inhibition of neuronal NOS reduced the delayed tachycardic response to hUII but did not significantly affect the vasodilatation. Only the initial tachycardic response to hUII was antagonised by propranolol. In spontaneously hypertensive rats (SHR), the initial haemodynamic responses to hUII were qualitatively similar to those in SD rats, although there was also a modest renal vasodilatation. The secondary response comprised a smaller tachycardia and a small rise in blood pressure, with no significant hindquarters vasodilatation. Haemodynamic responses to hUII were not enhanced by endothelin and angiotensin receptor antagonism in either SD rats or in SHRs. One interpretation of these results is that the primary response to bolus injection of hUII is prostanoid- or prostanoid- and NO-mediated (mesenteric vasodilatation) and that this triggers secondary events, which are dependent on eNOS (hindquarters vasodilatation) and neuronal NOS (tachycardia).

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15339862      PMCID: PMC1575352          DOI: 10.1038/sj.bjp.0705954

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  38 in total

1.  Peripheral vagal control of heart rate is impaired in neuronal NOS knockout mice.

Authors:  J K Choate; E J Danson; J F Morris; D J Paterson
Journal:  Am J Physiol Heart Circ Physiol       Date:  2001-12       Impact factor: 4.733

2.  Role of brain arachidonic acid cascade on central CRF1 receptor-mediated activation of sympatho-adrenomedullary outflow in rats.

Authors:  K Yokotani; Y Murakami; S Okada; M Hirata
Journal:  Eur J Pharmacol       Date:  2001-05-11       Impact factor: 4.432

3.  Involvement of the nitric oxide/L-arginine and sympathetic nervous systems on the vasodepressor action of human urotensin II in anesthetized rats.

Authors:  Aly M Abdelrahman; Catherine C Y Pang
Journal:  Life Sci       Date:  2002-07-05       Impact factor: 5.037

4.  Human urotensin II increases coronary perfusion pressure in the isolated rat heart: potentiation by nitric oxide synthase and cyclooxygenase inhibition.

Authors:  G A Gray; M R Jones; I Sharif
Journal:  Life Sci       Date:  2001-06-01       Impact factor: 5.037

5.  The influence of nitric oxide synthase 1 on blood flow and interstitial nitric oxide in the kidney.

Authors:  M Kakoki; A P Zou; D L Mattson
Journal:  Am J Physiol Regul Integr Comp Physiol       Date:  2001-07       Impact factor: 3.619

6.  Urotensin II evokes potent vasoconstriction in humans in vivo.

Authors:  Felix Böhm; John Pernow
Journal:  Br J Pharmacol       Date:  2002-01       Impact factor: 8.739

7.  Chronotropic effects of nitric oxide in the denervated human heart.

Authors:  S Chowdhary; D Harrington; R S Bonser; J H Coote; J N Townend
Journal:  J Physiol       Date:  2002-06-01       Impact factor: 5.182

8.  Vasodilator effect of urotensin II, one of the most potent vasoconstricting factors, on rat coronary arteries.

Authors:  Y Katano; A Ishihata; T Aita; T Ogaki; T Horie
Journal:  Eur J Pharmacol       Date:  2000-08-18       Impact factor: 4.432

9.  Interactions of adenosine, prostaglandins and nitric oxide in hypoxia-induced vasodilatation: in vivo and in vitro studies.

Authors:  Clare J Ray; Mark R Abbas; Andrew M Coney; Janice M Marshall
Journal:  J Physiol       Date:  2002-10-01       Impact factor: 5.182

10.  Nitric oxide synthase/PGE(2) cross-talk in rat submandibular gland.

Authors:  E Borda; G Heizig; L Busch; L Sterin-Borda
Journal:  Prostaglandins Leukot Essent Fatty Acids       Date:  2002-07       Impact factor: 4.006

View more
  8 in total

1.  Urotensin-II induces ear flushing in rats.

Authors:  J-s Qi; R Schulingkamp; T J Parry; R Colburn; D Stone; B Haertlein; L K Minor; P Andrade-Gordon; B P Damiano
Journal:  Br J Pharmacol       Date:  2007-01-08       Impact factor: 8.739

Review 2.  The role of urotensin II in cardiovascular and renal physiology and diseases.

Authors:  Yi-Chun Zhu; Yi-Zhun Zhu; Philip Keith Moore
Journal:  Br J Pharmacol       Date:  2006-06-19       Impact factor: 8.739

3.  Cell and tissue responses of a range of Urotensin II analogs at cloned and native urotensin II receptors. Evidence for coupling promiscuity.

Authors:  Wei Song; John McDonald; Valeria Camarda; Girolamo Calo; Remo Guerrini; Erika Marzola; Jonathan P Thompson; David J Rowbotham; David G Lambert
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2006-04-05       Impact factor: 3.000

4.  Nonpeptidic urotensin-II receptor antagonists I: in vitro pharmacological characterization of SB-706375.

Authors:  Stephen A Douglas; David J Behm; Nambi V Aiyar; Diane Naselsky; Jyoti Disa; David P Brooks; Eliot H Ohlstein; John G Gleason; Henry M Sarau; James J Foley; Peter T Buckley; Dulcie B Schmidt; William E Wixted; Katherine Widdowson; Graham Riley; Jian Jin; Timothy F Gallagher; Stanley J Schmidt; Lance Ridgers; Lisa T Christmann; Richard M Keenan; Steven D Knight; Dashyant Dhanak
Journal:  Br J Pharmacol       Date:  2005-07       Impact factor: 8.739

5.  Regional heterogeneity in the haemodynamic responses to urotensin II infusion in relation to UT receptor localisation.

Authors:  Sheila M Gardiner; Julie E March; Philip A Kemp; Janet J Maguire; Rhoda E Kuc; Anthony P Davenport; Terence Bennett
Journal:  Br J Pharmacol       Date:  2006-03       Impact factor: 8.739

6.  Murine and rat cavernosal responses to endothelin-1 and urotensin-II Vasoactive Peptide Symposium.

Authors:  Fernando S Carneiro; Zidonia N Carneiro; Fernanda R C Giachini; Victor V Lima; Edson Nogueira; William E Rainey; Rita C Tostes; R Clinton Webb
Journal:  J Am Soc Hypertens       Date:  2008-11

7.  The peptidic urotensin-II receptor ligand GSK248451 possesses less intrinsic activity than the low-efficacy partial agonists SB-710411 and urantide in native mammalian tissues and recombinant cell systems.

Authors:  David J Behm; Gerald Stankus; Christopher P A Doe; Robert N Willette; Henry M Sarau; James J Foley; Dulcie B Schmidt; Parvathi Nuthulaganti; James A Fornwald; Robert S Ames; David G Lambert; Girolamo Calo'; Valeria Camarda; Nambi V Aiyar; Stephen A Douglas
Journal:  Br J Pharmacol       Date:  2006-05       Impact factor: 8.739

8.  Characterization of Rat Cardiovascular System by Anacrotic/Dicrotic Notches in the Condition of Increase/Decrease of NO Bioavailability.

Authors:  Lenka Tomasova; Anton Misak; Lucia Kurakova; Marian Grman; Karol Ondrias
Journal:  Int J Mol Sci       Date:  2020-09-12       Impact factor: 5.923

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.